Navigation Links
Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA
Date:11/24/2008

- Action Date is July 18, 2009 -

LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA). The action date under the Prescription Drug User Fee Act (PDUFA) is July 18, 2009.

Labopharm's NDA for its novel trazodone formulation is based on data from five pivotal pharmacokinetic studies and the positive results from its North American Phase III placebo controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients. The Agency advised the Company that one positive Phase III study is required for the formulation to be approved.

About Labopharm's Novel Trazodone Formulation and the Market for Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
2. Novel imaging technique reveals brain abnormalities that may play key role in ADHD
3. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
4. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
5. Novel 4-drug combination proves safe for lung cancer treatment
6. Porter Novelli Named Agency of Record for Pharmavite(R) LLC
7. Completely novel action of insulin unveiled
8. Yo Mujer: Woman Escapes from Abusive Marriage in New Spanish-Language Novel
9. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
10. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
11. Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as ... new solution helps transform the HCC Risk Adjustment process from a typical ...
(Date:2/22/2017)... ... ... Sideline Products participated in the World Horse Expo held in Timonium, MD in ... crew. Tom Seay’s program “Best of America by Horseback” is broadcasted on RFD-TV ... featured on April 6, 2017. After the broadcast, the clip will be posted on ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... GA (PRWEB) , ... February 22, 2017 , ... Super-Sod ... 25 and 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens ... in Georgia. , For the booth, grass seed plant manager Chris Roquemore constructed furniture ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017 astic drugs ... type of antineoplastic drug aiming at functions at multiple ... in to a new stage. Download the ... there are nearly four million cases of new tumors ... aging of population, environmental pollution caused by industrialization and ...
(Date:2/22/2017)... YORK , Feb. 22, 2017 ... the atherosclerosis partnering deals and agreements entered into ... the full report: http://www.reportlinker.com/p03605675-summary/view-report.html Description ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
(Date:2/22/2017)... Summary Provides understanding and access ... entered into by the worlds leading healthcare companies. ... The Global Motor Neurone Disease Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... - Top deals by value - Deals ...
Breaking Medicine Technology: